ArticleFASEB bioAdvances2025
Enhancement of adipose stem cell quality via Cu-MON: Transcriptome and bioinformatics analysis of normal and diabetic stem cells.
Article in FASEB bioAdvances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Type 2 Diabetes-Induced Molecular and Functional Impairment of Adipose Tissue-Derived Mesenchymal Stromal Cells (ASCs) and Interferon Gamma Priming for Enhanced Diabetic ASC-Based Therapy.Stem cell reviews and reports · 2026Article
- Enhancement of adipose stem cell quality via Cu-MON: Transcriptome and bioinformatics analysis of normal and diabetic stem cells.FASEB bioAdvances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transplanted adipose stem cells (ASC) have a low survival rate in the body, and there are not many ASC that can be effectively used, which weakens their tissue repair function. Based on this status quo, a new type of copper-based metal-organic network (Cu-MON) was used to pretreat cells to regulate cell activity in order to improve the efficacy of cell therapy or reduce the number of cells used, thus reducing the cost of clinical treatment. Gene expression changes before and after Cu-MON treatment of normal donor adipose stem cells (ND-ASC) and type 2 diabetes mellitus adipose stem cells (T2DM-ASC) were evaluated through RNA sequencing, KEGG and GO enrichment analysis. The results showed that Cu-MON improved ASC cell quality by regulating immune response and promoting paracrine secretion. IL-17 signaling pathway and IL-6, CXCL8, and MMP-9 were key pathways and necessary genes that affected the ability of stem cells. In addition, Cu-MON also improved stem cell antiviral ability through Type I interferon signaling pathway. Our research showed that Cu-MON had improved the cell quality of ASC by regulating immune response, promoting paracrine secretion, and improving antiviral capabilities. This approach to biomaterial pretreatment is fast, convenient, and relatively safe, and provides new strategies for improving the efficiency of cell therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.